Author

I. A. McNeish

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Approach:statistical model· 6 Research Focus:differential expression· 4 Approach:experimental assay· 4 Assay:whole-genome sequencing· 4 Assay:bulk RNA-seq· 3 Research Focus:clustering· 3 Research Focus:gene regulatory network inference· 3

Frequent Co-Authors

C. Gourley· 3 shared D. Ennis· 3 shared H. B. Mirza· 3 shared J. D. Brenton· 3 shared A. Ewing· 2 shared A. Hoyle· 2 shared A. M. Piskorz· 2 shared A. Matakidou· 2 shared

Activity by Year

2017-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Gourley

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions

Z. Cheng, D. P. Ennis, B. Lu, H. B. Mirza, C. Sokota, B. Kaur, N. Singh, O. Le Saux, G. Russo, G. Giannone, L. A. Tookman, J. Krell, J. McDermott, C. Barnes, I. A. McNeish

This study shows that high ploidy and whole genome duplication in ovarian high-grade serous carcinoma originate in STIC lesions, indicating early determination of the tumor's genomic trajectory.

bioRxiv · Mar 11, 2024 · PreprintCancer Biology

Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer

A. Ewing, A. Meynert, R. Silk, S. Aitken, D. P. Bendixsen, M. Churchman, S. L. Brown, A. Hamdan, J. Mattocks, G. R. Grimes, T. Ballinger, R. L. Hollis, C. S. Herrington, J. P. Thomson, K. Sherwood, , C. A. Semple

The paper identifies two divergent structural variation trajectories in HGSOC that impact patient survival and reveals novel candidate driver genes and mtDNA mutations associated with prognosis.

bioRxiv · Jan 12, 2024Cancer Biology

Heme oxygenase-1 expressing omental macrophages as a therapeutic target in ovarian high grade serous carcinoma

S. Spear, O. Le Saux, H. B. Mirza, K. Tyson, J. Bickel, F. Grundland Freile, A. P. Siskos, C. Balcells, J. B. Walton, C. Woodman, D. P. Ennis, N. Iyer, C. Aguirre Hernandez, Y. Xu, P. Spiliopoulou, , I. A. McNeish

This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.

bioRxiv · Jul 18, 2023 · PreprintCancer Biology

PTEN deficiency exposes a requirement for an ARF GTPase module in integrin-dependent invasion in ovarian cancer.

K. Nikolatou, E. Sandilands, A. Roman-Fernandez, E. M. Cumming, E. C. Freckmann, S. Lilla, L. Buetow, L. McGarry, M. Neilson, R. Shaw, D. Strachan, C. Miller, D. T. Huang, I. A. McNeish, J. C. Norman, , D. Bryant

This study identifies ARF6 as a critical vulnerability in PTEN-deficient ovarian cancer, showing its role in integrin-dependent invasion and its inverse association with patient outcomes.

bioRxiv · Nov 29, 2022Cancer Biology

Molecular landscape and functional characterization of centrosome amplification in ovarian cancer

C. M. Sauer, J. A. Hall, D.-L. Couturier, T. Bradley, A. M. Piskorz, J. Griffiths, A. Sawle, M. D. Eldridge, P. Smith, K. Hosking, M. A. Reinius, L. Morrill Gavarro, A.-M. Mes-Masson, D. Ennis, D. Millan, , J. D. Brenton

This study identifies centrosome amplification as a common and heterogeneous feature in HGSOC, linked to CIN and treatment resistance.

bioRxiv · Sep 13, 2022Cancer Biology

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

R. M. Hurley, C. D. McGehee, K. Nesic, C. Correia, T. M. Weiskittel, R. L. Kelly, A. Venkatachalam, X. Hou, N. M. Pathoulas, X. W. Meng, O. Kondrashova, M. R. Radke, P. A. Schneider, K. S. Flatten, K. L. Peterson, , S. H. Kaufmann

This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.

bioRxiv · Dec 25, 2020Cancer Biology

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer

J. I. Hoare, H. Hockings, J. Saxena, V. L. Silva, E. Maniati, H. B. Mirza, W. Huang, G. E. Wood, F. Nicolini, T. A. Graham, I. A. McNeish, M. Lockley

This study investigates platinum resistance in high grade serous ovarian cancer by analyzing transcriptomic features and evolutionary trajectories in resistant models.

bioRxiv · Jul 23, 2020 · PreprintCancer Biology

Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma

A. Ewing, A. Meynert, M. Churchman, G. R. Grimes, R. L. Hollis, C. S. Herrington, T. Rye, C. Bartos, I. Croy, M. Ferguson, M. Lennie, T. McGoldrick, N. McPhail, N. Siddiqui, S. Dowson, , C. A. Semple

This study identifies large structural variants as a significant source of homologous repair deficiency in high-grade serous ovarian carcinoma, beyond known SNVs and indels at BRCA1/2.

bioRxiv · May 11, 2020Cancer Biology

Copy-number signatures and mutational processes in ovarian carcinoma

G. Macintyre, T. Goranova, D. De Silva, D. Ennis, A. M. Piskorz, M. Eldridge, D. Sie, L.-A. Lewsley, A. Hanif, C. Wilson, S. Dowson, R. M. Glasspool, M. Lockley, E. Brockbank, A. Montes, , J. D. Brenton

This study identifies copy-number signatures in ovarian cancer and links them to mutational processes, showing that most cases involve multiple processes, suggesting therapeutic challenges.

bioRxiv · Sep 4, 2017Cancer Biology